The R21/MatrixM antimalarial vaccine reduces symptomatic cases by up to 75%. The vaccine for which the data has now been released has been developed by researchers at the University of Oxford.
Its objective is to expand access to prevention through malaria vaccination. The development of immunizations for this disease has been, by the way, considered one of the scientific milestones of last year 2023, as EL MUNDO reported. Globally, there were an estimated 249 million malaria cases and 608,000 malaria deaths in 85 countries.